CMPX - Company ID 0001738021
The table below shows Compass Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$17.27M | -$13.21M | -$13.89M | -$12.23M | -$7.94M | -$5.61M |
| Capital expenditure | $82.00K | $18.00K | $0.00 | $0.00 | $194.00K | $128.00K |
| Investing cash flow | $38.43M | $11.59M | -$4.10M | $4.27M | -$193.00K | -$13.00K |
| Dividends paid | - | - | - |
Compass Therapeutics, Inc. reported operating cash flow of -$49.14M for fiscal year 2025. That is down 9.6% from -$44.85M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$32.76K (FY 2019) to -$49.14M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $3.37M | -$815.00K | $17.43M | $41.00K | $0.00 | -$1.88M |